Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma

Digestive Diseases and Sciences

Volumn 57, Issue 8, 2012, Pages 2233-2240

  Kleiner, David E ^a   Berman, David ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

CTLA 4; Drug induced hepatitis; Immunosuppressive therapy; Ipilimumab; Metastatic melanoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MELANOMA ANTIGEN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER IMMUNOTHERAPY; CASE REPORT; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; SIDE EFFECT; STEROID THERAPY; TOXIC HEPATITIS; TREATMENT OUTCOME; VITILIGO;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DRUG-INDUCED LIVER INJURY; FATAL OUTCOME; FEMALE; HUMANS; LIVER; MALE; MELANOMA; MIDDLE AGED;

EID: 84866385936     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2140-5     Document Type: Article

References (22)

1. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275-5283.
2. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008; 13:2-9.
3. Weber J, Thompson JA, Hamid O, et al. A randomized, doubleblind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598.
4. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-164.
5. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter, single-arm phase II study. Ann Oncol. 2010;21:1712-1717.
6. Maio M, Lebbé C, Neyns B, et al. Three-Year Survival Rates for Patients with Advanced Melanoma Who Received Ipilimumab at 10 mg/kg in Phase II Trials [Abstract]. In: Presented at the XIV annual meeting of the perspectives in melanoma, 2010 September 17-18, Amsterdam, The Netherlands. 2010.
7. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
8. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526. doi:10.1056/NEJMoa1104621.
9. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864-872.
10. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533-546.
11. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockades in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
12. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-6053.
13. Qiu D, Wang Q, Wang H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol. 2011;54:340-347.
14. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver Injury. Clin Pharmacol Ther. 2011;89:806-815.
15. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958-976.
16. Suriawinata AA, Thung SN. Acute and chronic hepatitis. Semin Diagn Pathol. 2006;23:132-148.
17. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758-2769.
18. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354: 54-66.
19. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931-939.
20. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11-21.
21. Sulz MC, Gerlach TJ. Autoimmune hepatitis. Ther Umsch. 2011; 68:189-194.
22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.